cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/6np0bt/l58gsi
title: Giugno_1894_Pagina_010.jpg

description: Bulletin of 1894/06/03
DOI: 10.13130/rd_unimi/v8alup/v5xnu6
title: Giugno_1891_Pagina_048.jpg

description: Bulletin of 1891/06/12
DOI: 10.25574/03157
title: Chandra X-ray Observatory ObsId 03157

description: A CHANDRA SURVEY OF THE MOST LUMINOUS QUASARS AT Z &gt; 4
DOI: 10.25934/pr00012250
title: A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

description: This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
DOI: 10.13130/rd_unimi/cbrkhv/zetzwb
title: Gennaio_1927_Pagina_042.jpg

description: Bulletin of 1927/01/11
DOI: 10.13130/rd_unimi/jvs9pt/aiqujh
title: Giugno_1892_Pagina_026.jpg

description: Bulletin of 1892/06/07
DOI: 10.13130/rd_unimi/nsvbhr/aczhgz
title: Giugno_1890_Pagina_052.jpg

description: Bulletin of 1890/06/13
DOI: 10.13130/rd_unimi/xu1sm0/ffkkxx
title: Giugno_1893_Pagina_027.jpg

description: Bulletin of 1893/06/07
DOI: 10.25934/pr00012251
title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome

description: This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
DOI: 10.13130/rd_unimi/gsbgp1/mhpex1
title: Giugno_1889_Pagina_068.jpg

description: Bulletin of 1889/06/17
DOI: 10.13130/rd_unimi/rjrjox/lla0pk
title: Luglio_1895_Pagina_069.jpg

description: Bulletin of 1895/07/18
DOI: 10.25934/pr00012252
title: A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens

description: This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.
DOI: 10.13130/rd_unimi/6np0bt/xzkgdd
title: Giugno_1894_Pagina_011.jpg

description: Bulletin of 1894/06/03
DOI: 10.13130/rd_unimi/awv4gb/xozek1
title: Giugno_1896_Pagina_005.jpg

description: Bulletin of 1896/06/02
DOI: 10.13130/rd_unimi/v8alup/1zjftv
title: Giugno_1891_Pagina_049.jpg

description: Bulletin of 1891/06/13
DOI: 10.25574/03158
title: Chandra X-ray Observatory ObsId 03158

description: A CHANDRA SURVEY OF THE MOST LUMINOUS QUASARS AT Z &gt; 4
DOI: 10.25934/pr00012253
title: An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens

description: This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
DOI: 10.13130/rd_unimi/cbrkhv/rb36rl
title: Gennaio_1927_Pagina_043.jpg

description: Bulletin of 1927/01/11
DOI: 10.13130/rd_unimi/nsvbhr/vvpac9
title: Giugno_1890_Pagina_053.jpg

description: Bulletin of 1890/06/14
DOI: 10.13130/rd_unimi/xu1sm0/qd7clo
title: Giugno_1893_Pagina_028.jpg

description: Bulletin of 1893/06/07
DOI: 10.25934/pr00012254
title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer

description: The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
DOI: 10.13130/rd_unimi/jvs9pt/waqlo9
title: Giugno_1892_Pagina_027.jpg

description: Bulletin of 1892/06/07
DOI: 10.13130/rd_unimi/rjrjox/lzfncw
title: Luglio_1895_Pagina_082.jpg

description: Bulletin of 1895/07/21
DOI: 10.25934/pr00012255
title: Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures

description: The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive procedures. The clinical benefit of eltrombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an invasive procedure. In addition, bleeding events will be monitored during this time. The number of transfusions, safety events and medical resource utilisation will be monitored during this time and for up to 30 days after undergoing an invasive procedure to help further evaluate clinical benefit.
DOI: 10.13130/rd_unimi/6np0bt/hneepv
title: Giugno_1894_Pagina_012.jpg

description: Bulletin of 1894/06/03
DOI: 10.13130/rd_unimi/awv4gb/nwdagb
title: Giugno_1896_Pagina_006.jpg

description: Bulletin of 1896/06/02
DOI: 10.13130/rd_unimi/v8alup/o1etcu
title: Giugno_1891_Pagina_050.jpg

description: Bulletin of 1891/06/13
DOI: 10.25574/03159
title: Chandra X-ray Observatory ObsId 03159

description: A CHANDRA SURVEY OF THE MOST LUMINOUS QUASARS AT Z &gt; 4
DOI: 10.25934/pr00012256
title: A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)

description: This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
DOI: 10.13130/rd_unimi/gsbgp1/h5aidx
title: Giugno_1889_Pagina_069.jpg

description: Bulletin of 1889/06/18
DOI: 10.13130/rd_unimi/nsvbhr/uz5of6
title: Giugno_1890_Pagina_054.jpg

description: Bulletin of 1890/06/14
DOI: 10.13130/rd_unimi/xu1sm0/shttht
title: Giugno_1893_Pagina_029.jpg

description: Bulletin of 1893/06/08
DOI: 10.25934/pr00012257
title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

description: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
DOI: 10.13130/rd_unimi/cbrkhv/18rqmz
title: Gennaio_1927_Pagina_044.jpg

description: Bulletin of 1927/01/11
DOI: 10.13130/rd_unimi/jvs9pt/1nrmfh
title: Giugno_1892_Pagina_028.jpg

description: Bulletin of 1892/06/07
DOI: 10.25934/pr00012258
title: 24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

description: This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
DOI: 10.13130/rd_unimi/awv4gb/zvogcy
title: Giugno_1896_Pagina_007.jpg

description: Bulletin of 1896/06/02
DOI: 10.13130/rd_unimi/gsbgp1/fhg5nd
title: Giugno_1889_Pagina_070.jpg

description: Bulletin of 1889/06/18
DOI: 10.13130/rd_unimi/rjrjox/7cc7ef
title: Luglio_1895_Pagina_083.jpg

description: Bulletin of 1895/07/21
DOI: 10.13130/rd_unimi/v8alup/pk7gmf
title: Giugno_1891_Pagina_051.jpg

description: Bulletin of 1891/06/13
DOI: 10.25574/03160
title: Chandra X-ray Observatory ObsId 03160

description: A CHANDRA SURVEY OF THE MOST LUMINOUS QUASARS AT Z &gt; 4
DOI: 10.25934/pr00012259
title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens

description: The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
DOI: 10.13130/rd_unimi/6np0bt/dwilgt
title: Giugno_1894_Pagina_013.jpg

description: Bulletin of 1894/06/04
DOI: 10.13130/rd_unimi/xu1sm0/bukoow
title: Giugno_1893_Pagina_030.jpg

description: Bulletin of 1893/06/08
DOI: 10.25934/pr00012260
title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

description: The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
DOI: 10.13130/rd_unimi/cbrkhv/q1oa3g
title: Gennaio_1927_Pagina_045.jpg

description: Bulletin of 1927/01/12
DOI: 10.13130/rd_unimi/nsvbhr/quwg9d
title: Giugno_1890_Pagina_055.jpg

description: Bulletin of 1890/06/14
DOI: 10.25934/pr00012261
title: A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures.

description: This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
DOI: 10.13130/rd_unimi/jvs9pt/hycw1c
title: Giugno_1892_Pagina_029.jpg

description: Bulletin of 1892/06/08
DOI: 10.13130/rd_unimi/rjrjox/npwacs
title: Luglio_1895_Pagina_084.jpg

description: Bulletin of 1895/07/21
DOI: 10.13130/rd_unimi/v8alup/zaepxb
title: Giugno_1891_Pagina_052.jpg

description: Bulletin of 1891/06/13
DOI: 10.25574/03180
title: Chandra X-ray Observatory ObsId 03180

description: MEASURING THE MASS DISTRIBUTION IN THE MOST DISTANT,VERY X-RAY LUMINOUS GALAXY CLUSTER KNOWN
DOI: 10.25934/pr00012262
title: A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.

description: This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
DOI: 10.25934/pr00012263
title: BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain

description: This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.
DOI: 10.13130/rd_unimi/awv4gb/xtidvr
title: Giugno_1896_Pagina_008.jpg

description: Bulletin of 1896/06/02
DOI: 10.13130/rd_unimi/gsbgp1/efjdwf
title: Giugno_1889_Pagina_071.jpg

description: Bulletin of 1889/06/18
DOI: 10.13130/rd_unimi/6np0bt/rkvec2
title: Giugno_1894_Pagina_014.jpg

description: Bulletin of 1894/06/04
DOI: 10.13130/rd_unimi/xu1sm0/6qwycv
title: Giugno_1893_Pagina_031.jpg

description: Bulletin of 1893/06/08
DOI: 10.25934/pr00012264
title: A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)

description: A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
DOI: 10.13130/rd_unimi/cbrkhv/zwfex1
title: Gennaio_1927_Pagina_046.jpg

description: Bulletin of 1927/01/12
DOI: 10.13130/rd_unimi/jvs9pt/ishfcw
title: Giugno_1892_Pagina_030.jpg

description: Bulletin of 1892/06/08
DOI: 10.13130/rd_unimi/nsvbhr/m7cvtg
title: Giugno_1890_Pagina_056.jpg

description: Bulletin of 1890/06/14
DOI: 10.25934/pr00012265
title: An Open Phase III Trial With Letrozole Alone or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

description: This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received 4 to 6 years of adjuvant tamoxifen therapy after resection of the tumor. Patients were treated with letrozole 2.5 mg orally per day or letrozole 2.5 mg orally per day in combination with zoledronic acid 4 mg/6 months as an infusion.This trial did not recruit patients in the United States.
DOI: 10.13130/rd_unimi/rjrjox/6rmvn3
title: Luglio_1895_Pagina_086.jpg

description: Bulletin of 1895/07/22
DOI: 10.13130/rd_unimi/v8alup/kwgmpl
title: Giugno_1891_Pagina_053.jpg

description: Bulletin of 1891/06/14
DOI: 10.25574/03181
title: Chandra X-ray Observatory ObsId 03181

description: A NEW GALAXY CLUSTER STRONG LENS
DOI: 10.25934/pr00012266
title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer

description: RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing disease progression.PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in treating patients who have solid tumors that have spread to the bone.
DOI: 10.13130/rd_unimi/awv4gb/olaehs
title: Giugno_1896_Pagina_009.jpg

description: Bulletin of 1896/06/03
DOI: 10.13130/rd_unimi/gsbgp1/0tzqdk
title: Giugno_1889_Pagina_072.jpg

description: Bulletin of 1889/06/18
DOI: 10.15468/dl.q8fe57
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Phomopsis lokoyae G.G.Hahn",
 {
 "not" : {
 "DatasetKey" : [
 "is Global database of alien macrofungi"
 ]
 }
 },
 {
 "or" : [
 "Country is United States of America",
 "Country is United States",
 "Country is United States of America",
 "Country is Canada",
 "Continent is North America"
 ]
 }
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0133914-210914110416597/datasets/export for details.
DOI: 10.15468/dl.lrkbcm
title: Occurrence Download

description: A dataset containing 104 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Year 2000-2019",
 "HasCoordinate is true",
 "TaxonKey is Damasonium polyspermum Coss.",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 104 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0025141-190918142434337/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qurs54
title: Occurrence Download

description: A dataset containing 182 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Lophodermium nitens Darker",
 {
 "not" : {
 "DatasetKey" : [
 "is Global database of alien macrofungi"
 ]
 }
 },
 {
 "or" : [
 "Country is United States of America",
 "Country is United States",
 "Country is United States of America",
 "Country is Canada",
 "Continent is North America"
 ]
 }
 ]
}

 The dataset includes 182 records from 16 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0133099-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.sxvbm7
title: Occurrence Download

description: A dataset containing 1036166 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Centre for Australian National Biodiversity Research (CANB) AVH data"
 ]
}

 The dataset includes 1036166 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0278539-220831081235567/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.3mq9q6
title: Occurrence Download

description: A dataset containing 2876 species occurrences available in GBIF matching the query:
{
 "or" : [
 "TaxonKey is Picea obovata Ledeb.",
 "TaxonKey is Populus ×jrtyschensis Chang Y.Yang"
 ]
}

 The dataset includes 2876 records from 79 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0212905-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.8ngce5
title: Occurrence Download

description: A dataset containing 75823 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((97 -23.436,190 -23.436,190 23.436,97 23.436,97 -23.436))",
 "HasCoordinate is true",
 {
 "or" : [
 "TaxonKey is Alcyonacea",
 "TaxonKey is Helioporacea",
 "TaxonKey is Pennatulacea"
 ]
 }
 ]
}

 The dataset includes 75823 records from 84 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0129038-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.dcuauj
title: Occurrence Download

description: A dataset containing 311 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON ((-118.3695474000000019 34.0346778999999984, -118.3695474000000019 34.0368271800000031, -118.3695474000000019 34.0398975800000017, -118.3695474000000019 34.0415862999999987, -118.3695474000000019 34.0451172599999978, -118.3695474000000019 34.0475735799999981, -118.3695474000000019 34.0500298999999984, -118.3658660400000002 34.0500298999999984, -118.3626449599999972 34.0500298999999984, -118.3588103499999988 34.0500298999999984, -118.3558960499999984 34.0500298999999984, -118.3522148200000004 34.0500298999999984, -118.3494539000000003 34.0500298999999984, -118.3451591299999990 34.0500298999999984, -118.3431649999999991 34.0500298999999984, -118.3431649999999991 34.0463454200000015, -118.3431649999999991 34.0441961399999968, -118.3431649999999991 34.0409722200000004, -118.3431649999999991 34.0372877399999965, -118.3431649999999991 34.0346778999999984, -118.3463862100000057 34.0346778999999984, -118.3508343599999932 34.0346778999999984, -118.3526749699999954 34.0346778999999984, -118.3552825099999950 34.0346778999999984, -118.3591171199999934 34.0346778999999984, -118.3621848100000022 34.0346778999999984, -118.3644855799999931 34.0346778999999984, -118.3673998799999936 34.0346778999999984, -118.3695474000000019 34.0346778999999984))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1932",
 "BasisOfRecord is one of (Human Observation, Living Specimen, Observation, Specimen, Machine Observation)"
 ]
}

 The dataset includes 311 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091176-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.tbkn2j
title: Occurrence Download

description: A dataset containing 2189 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Germany",
 "TaxonKey is Procyon lotor (Linnaeus, 1758)"
 ]
}

 The dataset includes 2189 records from 21 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0212941-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.v5pnxy
title: Occurrence Download

description: A dataset containing 297 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON ((-118.3090447999999952 33.9892500999999996, -118.3090447999999952 33.9936237900000009, -118.3090447999999952 33.9976475799999989, -118.3090447999999952 34.0021962200000019, -118.3090447999999952 34.0053452800000002, -118.3090447999999952 34.0079694900000007, -118.3090447999999952 34.0109435999999974, -118.3090447999999952 34.0130429700000008, -118.3090447999999952 34.0160170799999975, -118.3090447999999952 34.0182914000000025, -118.3058870400000018 34.0182914000000025, -118.3032555799999983 34.0182914000000025, -118.2981680799999964 34.0182914000000025, -118.2944840300000067 34.0182914000000025, -118.2915016999999978 34.0182914000000025, -118.2915016999999978 34.0135678199999987, -118.2915016999999978 34.0112935000000007, -118.2915016999999978 34.0079694900000007, -118.2915016999999978 34.0037707500000010, -118.2915016999999978 34.0007966399999972, -118.2915016999999978 33.9962480000000014, -118.2915016999999978 33.9932738899999976, -118.2915016999999978 33.9892500999999996, -118.2967646299999984 33.9892500999999996, -118.3000978200000048 33.9892500999999996, -118.3029047100000071 33.9892500999999996, -118.3069396300000022 33.9892500999999996, -118.3090447999999952 33.9892500999999996))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1932",
 "BasisOfRecord is one of (Human Observation, Living Specimen, Observation, Specimen, Machine Observation)"
 ]
}

 The dataset includes 297 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091191-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.u3kek8
title: Occurrence Download

description: A dataset listing the 2 species recorded in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "TaxonKey is Marsilea batardae Launert"
 ]
}

 The dataset's 2 records were derived from 24 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0129053-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.